West Pharmaceutical
730 hedge funds and large institutions have $32B invested in West Pharmaceutical in 2021 Q4 according to their latest regulatory filings, with 136 funds opening new positions, 278 increasing their positions, 226 reducing their positions, and 63 closing their positions.
116% more first-time investments, than exits
New positions opened: 136 | Existing positions closed: 63
23% more repeat investments, than reductions
Existing positions increased: 278 | Existing positions reduced: 226
22% more funds holding in top 10
Funds holding in top 10: 9 → 11 (+2)
13% more capital invested
Capital invested by funds: $28.4B → $32B (+$3.57B)
9% more funds holding
Funds holding: 669 → 730 (+61)
2.68% more ownership
Funds ownership: 91.11% → 93.8% (+2.7%)
30% less call options, than puts
Call options by funds: $63.3M | Put options by funds: $90.2M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$496M |
| 2 |
BlackRock
New York
|
+$286M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$113M |
| 4 |
Morgan Stanley
New York
|
+$67.4M |
| 5 |
Man Group
London,
United Kingdom
|
+$56.1M |
Top Sellers
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$117M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$107M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$75.3M |
| 4 |
Neuberger Berman Group
New York
|
-$56.6M |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$56.3M |
WST Hedge Fund Activity: Q4 2021 in Review
730 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q4 2021, worth a combined $32B — up 13% from $28.4B a quarter earlier.
Buyers outnumbered sellers: 136 funds opened new WST positions and 63 closed out — a net gain of 73 holders — while 278 added to existing stakes and 226 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $496M. The largest seller was Victory Capital Management, cutting an estimated $117M.
- 730 institutional investors held West Pharmaceutical (WST) as of Q4 2021, up from 669 in Q3 2021.
- Funds reported $32B of West Pharmaceutical stock for Q4 2021, up 13% quarter-over-quarter.
- 136 funds opened new West Pharmaceutical positions in Q4 2021 and 63 closed out, a net change of +73 holders.
- The largest West Pharmaceutical buyer in Q4 2021 was T. Rowe Price Associates, an estimated $496M added.
- The largest West Pharmaceutical seller in Q4 2021 was Victory Capital Management, an estimated $117M sold.
Based on aggregated 13F filings for Q4 2021.